DWC202207

DWC202207 is an investigational pharmaceutical drug being developed by Daewoong Pharmaceutical for the treatment of hyperlipidemia and hypertension. It is currently in phase 3 clinical trials, primarily studied as part of a co-administration regimen with DWC202206 in patients who have both hypertension and hyperlipidemia. The primary endpoints in these studies are changes in mean sitting systolic blood pressure (MSSBP) and low-density lipoprotein cholesterol (LDL-C) from baseline. The specific mechanism of action, molecular target, modality, and active ingredient for DWC202207 have not been publicly disclosed as of June 2025[2][4][7][9].